Anzeige
Mehr »
Freitag, 31.10.2025 - Börsentäglich über 12.000 News
Attestation ist die Killer-App - Republic baut sie jetzt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0ESMG | ISIN: FR0010259150 | Ticker-Symbol: I7G
Tradegate
30.10.25 | 18:40
122,10 Euro
+0,08 % +0,10
1-Jahres-Chart
IPSEN SA Chart 1 Jahr
5-Tage-Chart
IPSEN SA 5-Tage-Chart
RealtimeGeldBriefZeit
121,80121,9014:49
121,70121,9014:35

Aktuelle News zur IPSEN Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiIpsen Pharma: IPSEN - Buy-back programme - Art 5 of MAR - Week 43 - 20253
IPSEN Aktie jetzt für 0€ handeln
24.10.Ipsen's educational push offers guidance to young adults switching from pediatric to adult healthcare2
23.10.Ipsen to acquire ImCheck Therapeutics in a deal worth up to €1bn3
23.10.Ipsen to buy French biotech company ImCheck Therapeutics1
22.10.Ipsen writes check worth up to €1B to acquire next-gen cancer biotech2
22.10.Starkes Q3 2025: Ipsen steigert Umsatz um 13,7 % und hebt Jahresprognose an10
22.10.Ipsen buys ImCheck, adding mid-stage leukaemia drug-
22.10.Ipsen expands oncology portfolio with €1B acquisition of French biotech ImCheck Therapeutics2
22.10.Ipsen Q3 Total Sales Rise, Lifts FY25 Outlook; To Buy ImCheck; Stock Up278PARIS (dpa-AFX) - Ipsen S.A. (IPSEY, IPN.PA), a specialty-care biopharmaceutical company, Wednesday reported higher total sales for the third quarter compared to last year, mainly driven by...
► Artikel lesen
22.10.Ipsen stock jumps 6% after upbeat Q3 and higher outlook on Somatuline boost11
22.10.EQT Life Sciences' ImCheck Therapeutics to be acquired by Ipsen in a transaction valued at up to EUR 1 billion280Ipsen and ImCheck Therapeutics have entered into a definitive share purchase agreement. ImCheck's shareholders will be eligible to receive a payment of EUR 350 million and downstream...
► Artikel lesen
22.10.Ipsen To Buy ImCheck Therapeutics In Up To $1 Bln Deal; Stock Up261PARIS (dpa-AFX) - Ipsen S.A. (IPSEY, IPN.PA), a biopharmaceutical company, Wednesday announced that it entered into a definite agreement to purchase ImCheck Therapeutics for a total consideration...
► Artikel lesen
22.10.Ipsen S.A. reports Q3 results; upgrades FY outlook2
22.10.EQS-News: Andera Partners: Ipsen to acquire ImCheck Therapeutics, in Andera Partners' portfolio, expanding its leadership in oncology, strengthening its pipeline225EQS-News: Andera Partners / Key word(s): Mergers & Acquisitions Ipsen to acquire ImCheck Therapeutics, in Andera Partners' portfolio, expanding its leadership in oncology, strengthening...
► Artikel lesen
22.10.GIMV: Gimv Life Sciences realizes successful exit with the sale of its stake in Imcheck Therapeutics to Ipsen2
22.10.Ipsen Pharma: Ipsen delivers strong sales in the first nine months of 2025 and further upgrades its full-year guidance373Year-to-date total sales growth of 12.1% at CER1, or 9.6% as reported, driven by all three therapeutic areas and including strong performance from Iqirvo®, Bylvay® and Somatuline® Further upgrade of...
► Artikel lesen
22.10.Ipsen Pharma: Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology, strengthening its pipeline434Acquisition focused on lead clinical-stage program ICT01 in acute myeloid leukemia, where data from the ongoing Phase I/II EVICTION trial showed high treatment response ICT01 has the potential to be...
► Artikel lesen
21.10.Ipsen Pharma: IPSEN - Buy-back programme - Art 5 of MAR - Week 42 - 20254
15.10.Ipsen Pharma: IPSEN - Buy-back programme - Art 5 of MAR - Week 41 - 20251
07.10.Ipsen Pharma: IPSEN - Buy-back programme - Art 5 of MAR - Week 40 - 20252
Weiter >>
90 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1